Biogenvs.Neurocrine Biosciences
BIIB vs NBIX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Biogen is about 1.7× larger than Neurocrine Biosciences by market cap; Biogen trades at the lower P/E (21.3 vs 26.4); year to date, Neurocrine Biosciences leads (+24.9% vs +13.2%).
Side by side
| BIIB | NBIX | |
|---|---|---|
| Market cap | $29.3B | $17.7B |
| Price | $199.15 | $177.11 |
| Today | +0.1% | −1.9% |
| Return YTD | +13.2% | +24.9% |
| Return 1Y | +47.2% | +31.3% |
| P/E | 21.3 | 26.4 |
| P/S | 2.9 | 5.7 |
| P/B | 1.6 | 5.2 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
BiogenBIIB
American biotech company focused on neurological diseases — including Alzheimer's (Leqembi, with Eisai) and MS.
Full BIIB profile →Neurocrine BiosciencesNBIX
Biopharma focused on neurological and endocrine diseases (Ingrezza).
Full NBIX profile →More comparisons in Biotech & innovation
See where BIIB and NBIX sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →